Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Soleno Therapeutics, Inc.

Clinical trials sponsored by Soleno Therapeutics, Inc., explained in plain language.

Soleno Therapeutics, Inc. SLNO NASDAQ

A biopharmaceutical company developing treatments for rare diseases, including Prader-Willi syndrome.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1

New drug under observation for rare genetic disorder

Disease control ENROLLING_BY_INVITATION

This study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers will track side effects and how the drug affects their health over time. The goal is to gather more safety information, not to test if the drug cures the condition.

Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control

Last updated Aug 15, 2026 00:00 UTC